Clinical Trial Update: Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis [Phase 3]

View source ↗

Summary

This clinical trial update reports efficacy and safety results from a Phase 3 study of oral BG00012 (dimethyl fumarate) versus an active reference in relapsing-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Tecfidera (dimethyl fumarate)

Snippet

Sponsor: Biogen | Conditions: Relapsing-Remitting Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2014-06-02